Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBK-01 vs Fidaxomicin for Primary or Recurrent Clostridioides Difficile Infection
NCT05201079Phase 3Completed
- Sponsor
- Mikrobiomik
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of MBK-01 in Clostridioides difficile infection (CDI), sponsored by Mikrobiomik. Started Oct 2021; status: completed.
02
Drugs
MBK-01
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05201079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201079.